Free Trial
NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

Enzo Biochem logo
$0.52 -0.01 (-2.33%)
As of 02/21/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Enzo Biochem Stock (NYSE:ENZ)

Key Stats

Today's Range
$0.51
$0.53
50-Day Range
$0.48
$1.02
52-Week Range
$0.41
$1.40
Volume
73,058 shs
Average Volume
151,622 shs
Market Capitalization
$26.96 million
P/E Ratio
N/A
Dividend Yield
77.52%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Enzo Biochem Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

ENZ MarketRank™: 

Enzo Biochem scored higher than 30% of companies evaluated by MarketBeat, and ranked 797th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Enzo Biochem.

  • Percentage of Shares Shorted

    0.79% of the float of Enzo Biochem has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzo Biochem has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enzo Biochem has recently decreased by 3.61%, indicating that investor sentiment is improving.
  • Dividend Leadership

    Enzo Biochem is a leading dividend payer. It pays a dividend yield of 77.21%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Enzo Biochem does not have a long track record of dividend growth.

  • Read more about Enzo Biochem's dividend.
  • Percentage of Shares Shorted

    0.79% of the float of Enzo Biochem has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzo Biochem has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enzo Biochem has recently decreased by 3.61%, indicating that investor sentiment is improving.
  • News Sentiment

    Enzo Biochem has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enzo Biochem this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for ENZ on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Enzo Biochem to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enzo Biochem insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.40% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.90% of the stock of Enzo Biochem is held by institutions.

  • Read more about Enzo Biochem's insider trading history.
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
NYSE notifies Enzo Biochem not in compliance with certain requirements
See More Headlines

ENZ Stock Analysis - Frequently Asked Questions

Enzo Biochem's stock was trading at $0.7143 on January 1st, 2025. Since then, ENZ stock has decreased by 27.8% and is now trading at $0.5160.
View the best growth stocks for 2025 here
.

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings results on Monday, December, 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 7.96% and a negative net margin of 75.34%.

Top institutional investors of Enzo Biochem include Renaissance Technologies LLC (4.53%), Mink Brook Asset Management LLC (1.55%), Wittenberg Investment Management Inc. (0.36%) and Lepercq De Neuflize Asset Management LLC (0.24%). Insiders that own company stock include James G Wolf, Hamid Erfanian, David Bench and Kara Cannon.
View institutional ownership trends
.

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

Ex-Dividend for 12/2 Dividend
11/15/2024
Dividend Payable
12/02/2024
Last Earnings
12/16/2024
Today
2/22/2025
Next Earnings (Estimated)
3/11/2025
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Employees
520
Year Founded
1976

Profitability

Net Income
$-26,080,000.00
Pretax Margin
-23.79%

Debt

Sales & Book Value

Annual Sales
$31.91 million
Book Value
$1.09 per share

Miscellaneous

Free Float
46,288,000
Market Cap
$26.96 million
Optionable
Optionable
Beta
0.81

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:ENZ) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners